Serious Adverse Event (SAE)
A serious adverse event is one meeting a defined regulatory outcome threshold such as death, a life-threatening episode, hospitalisation, persistent disability or a congenital anomaly.
Seriousness is a regulatory classification about outcome, not a description of how unpleasant something felt. An adverse event is serious if it results in death, is life-threatening, requires or prolongs inpatient hospitalisation, causes persistent or significant disability or incapacity, or produces a congenital anomaly, plus a catch-all for important medical events that required intervention to prevent one of those outcomes. This list has been harmonised internationally for decades.
The word most often confused with it is severe. Severity grades intensity, usually on a mild, moderate or severe scale, and the two dimensions are independent. A severe migraine managed at home is not serious; an asymptomatic arrhythmia found incidentally that leads to an overnight admission is. Seriousness drives reporting speed, with fatal or life-threatening unexpected suspected reactions expedited in seven days and other such reactions in fifteen.
The classification exists because it triages attention. Serious events are what a data monitoring committee reads first, what stopping rules are written around, and what regulators expect to be reconciled between a sponsor database and the trial dataset. In a safety table the serious column is the one that survives editorial compression, so it disproportionately shapes how a drug is perceived.
Two inferences do not follow from a serious event count. It is not a causality statement, which is recorded separately, so events unrelated to treatment still appear. And it is not comparable across programmes without adjusting for exposure and population, since a trial following several thousand middle-aged participants for more than a year will accrue hospitalisations for reasons that have nothing to do with the drug in either arm.